Meta AnalysisID 5653
安宫牛黄丸、醒脑静注射液、清开灵注射液辅助治疗缺血性卒中：随机对照试验的网状Meta分析
CRD42022296312
This network meta-analysis aim to evaluate the efficacy and safety of Angong Niuhuang Pill, Xingnaojing Injection, Qingkailing Injection as adjuvant therapies in patients with Ischemic stroke.
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 5653
- Evidence Id
- 14211
- Core Evidence Id
- 14211
- Source Meta Analysis Id
- 5634
- Herb2 Meta Analysis Id
- HBMA005634
- Crd Id
- CRD42022296312
- Title
- Angong Niuhuang Pill, Xingnaojing Injection, Qingkailing Injection as adjuvant therapies for treating ischemic stroke: A network meta-analysis of randomized controlled trials
- Review Question
- This network meta-analysis aim to evaluate the efficacy and safety of Angong Niuhuang Pill, Xingnaojing Injection, Qingkailing Injection as adjuvant therapies in patients with Ischemic stroke.
- Study Type Included
- Randomized clinical trials will be included irrespective of blinding, publication status or language.
- Condition Being Studied
- Despite advance in medical care, stroke remains the second leading cause of mortality and the main cause of disability worldwide. According to its underlying pathology, stroke can be grouped into ischemic, hemorrhagic or subarachnoid. Ischemic stroke accounts for approximately 67.3–80.5% of all strokes. Cerebral infarction is the most common subtype of ischemic stroke. Current therapeutic approaches for ischemic stroke mainly focus on expanding cerebral blood vessels and improving cerebral metabolism. Traditional Chinese Medicine (TCM) has been proposed as a potential candidate for the treatment of stroke. Angong Niuhuang Pill (ANP), a well-known traditional Chinese patent medicine, has been widely used in China. Xingnaojing injection and Qingkailing injection are improved traditional Chinese medicine injections based on Angong Niuhuang pill. ANP has been used to manage patients with various acute cerebrovascular diseases, such as encephalitis, meningitis, cerebral infarction, intracerebral hemorrhage.
- Participant
- Trials satisfying the following inclusion criteria were included: 1)RCTs evaluating the efficacy of Angong Niuhuang Pill、Xingnaojing Injection or Qingkailing Injection as adjuvant treatment (One of the three preparations plus usual treatment versus usual treatment alone) for Ischemic stroke; 2) Ischemic stroke was confirmed by computed tomography or magnetic resonance imaging scans; and 3) reported at least total response rate, improvement in neurologic deficit score according to the National Institutes of Health Stroke Scale (NIHSS), or adverse events as outcome measures. Total response rate was calculated by the total number of cases with symptoms of improvement (cure+significant improvement+ improvement)/total number of cases who received treatment. Exclusion criteria were the following: 1) non-clinical RCT and fundamental research;2)any differences in the intervention except for these three preparations treatment between two groups;3) enrolling all types of stroke patients;4) clinical studies without any control groups or subjects who did not meet the inclusion criteria; 5) studies with insufficient data or irrelevant topics.
- Animal
- Human Disease Modelled
- Intervention
- One of the three interventions, Angong Niuhuang Pill, Xingnaojing injection and Qingkailing injection, plus western medicine treatment, including monitoring vital signs, oxygen inhalation, dehydration, regulating blood pressure and blood sugar, regulating water-electrolyte acid-base imbalance, anticoagulation, anti-platelet aggregation, improving brain metabolism and other symptomatic support treatment. The dosage and course of these treatments are unlimited.
- Comparator Control
- Western medicine treatment, including monitoring vital signs, oxygen inhalation, dehydration, regulating blood pressure and blood sugar, regulating water-electrolyte acid-base imbalance, anticoagulation, anti-platelet aggregation, improving brain metabolism and other symptomatic support treatment. The dosage and course of these treatments are unlimited.
- Main Outcome
- Total response rate, improvement in neurologic deficit score according to the National Institutes of Health Stroke Scale (NIHSS), and adverse events. Measures of effect The measurement data NIHSS score used the weighted mean difference (MD), and its 95% confidence interval (CI) represented the effect size. The count data total response rate used the odds ratio (OR), and its 95% CI represented the effect size.
- Outcome Measure
- Additional Outcome
- Incidence of adverse events. Measures of effect The count data incidence of adverse events used the odds ratio (OR), and its 95% CI represented the effect size.
- Study Method
- Network meta-analysis, Systematic review
- Keyword
- Angong Niuhuang Pill; Humans; Ischemic Stroke; Network Meta-Analysis; Qingkailing; Randomized Controlled Trials as Topic; xingnaojing
- Contact
- Lu yu Xu [email protected]
- Organisational Affiliation
- Guangzhou University of Chinese Medicine
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-12-04
- Registration Date
- 2022-01-04
- Anticipated Start Date
- 2021-12-11
- Anticipated Completion Date
- 2022-06-11
- Title Cn
- 安宫牛黄丸、醒脑静注射液、清开灵注射液辅助治疗缺血性卒中：随机对照试验的网状Meta分析
- Title En
- Angong Niuhuang Pill, Xingnaojing Injection, Qingkailing Injection as adjuvant therapies for treating ischemic stroke: A network meta-analysis of randomized controlled trials
- Bilingual Status
- complete